SEARCH

SEARCH BY CITATION

References

  • 1
    Martı´nez-Pin˜eiro JA, Muntan˜ola P. L’Immunostimulation aspecifique avec vaccin BCG dans les tumeurs vesicales. Proces Verbaux, Memories et Discussions du 69e Session de l'Association Francaise d'Urologie. Paris: Edition Masson, 1975: 7248
  • 2
    Morales A, Edinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 1803
  • 3
    Rintala E, Jauhiainen K, Alfthan O et al. Mitomycin C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. In DebruyneF, DenisL, Van Der MeijdenAPM eds, EORTC Genito-Urinary Group Monograph 6: BCG in superficial Bladder Cancer. New York: Alan R Liss 1989: 2714
  • 4
    Pagano F, Bassi P, Milani C et al. Low-dose BCG Pasteur strain in the treatment of superficial bladder cancer: preliminary results. In DebruyneF, DenisL, Van Der MeijdenAPM eds, EORTC Genito-Urinary Group Monograph 6: BCG in superficial Bladder Cancer. New York: Alan R Liss 1989: 25661
  • 5
    Martı´nez-Pin˜eiro JA, Solsona E, Flores N, Isorna S and Cooperative Group CUETO. Improving the safety of BCG immunotherapy by dose reduction. Eur Urol 1995; 27 (Suppl. 81): 138
  • 6
    Sylvester RJ, Bijnens L, Denis LJ et al. A combined analysis of EORTC and MRC randomized trials for the prophylactic treatment of stage Ta T1 bladder cancer: prognostic factors and risk groups. J Urol 1997; 157: 215 (Abstract 839)
  • 7
    Bassi P, Nicola P, Spinadin R, Carando R, Pagano F, Papagallo GL. Low dose vs standard dose BCG therapy of superficial bladder cancer: final results of a phase 3 randomized trial. Eur Urol 1999; 35 (Suppl. 2): Abstract 152
  • 8
    Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 11249
  • 9
    Morales A, Nickel JC, Wilson JW. Dose-response of Bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol 1992; 147: 12568
  • 10
    Takashi M, Wakai K, Ohno Y, Murase T, Miyake K. Evaluation of low-dose Bacillus Calmette-Guerin (Tokyo strain) therapy for superficial bladder cancer. Int Urol Nephrol 1995; 27: 72333
  • 11
    Lebret T, Gaudez F, Herve JM, Barre P, Lugagne PM, Botto H. Low-dose BCG instillations in the treatment of stage T1 Grade 3 bladder tumours: recurrence, progression and success. Eur Urol 1998; 34: 6772
  • 12
    Moyano Calvo JL, Ortiz A, Romero A et al. Profilaxis de los tumores de vejiga estadio T1 con 27 mg de BCG semanales durante 6 semanas. Arch Esp Urol 1999; 52: 7608
  • 13
    Lebret T, Bohin D, Kassardjian Z et al. Recurrence, progression and success in stage Ta Grade 3 bladder tumors treated with low-dose Bacillus Calmette-Guerin instillations. J Urol 2000; 163: 637
  • 14
    Mack D, Frick J. Low-dose bacille Calmette-Guerin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada. Br J Urol 1995; 75: 1857
  • 15
    Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A. Low-dose Pasteur bacillus Calmette-Guerin regimen in stage T1 Grade 3 bladder cancer therapy. J Urol 1996; 156: 16025
  • 16
    Losa A, Hurle R, Lembo A. Low-dose Bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 2000; 163: 6822
  • 17
    Rivera P, Orio M, Hinostroza J et al. Nuestra experiencia con instilaciones de 1 mg de vacuna BCG en cancer vesical etapa T1. Actas Urol Esp 1999; 23: 75762
  • 18
    Rivera P, Inostroza J. Respuesta de linfocitos y linfokinas en pacientes portadores de cáncer veiscal superficial tratados con instilaciones de 1 mg de vacuna BCG. Actas Urol Esp 1996; 20: 8127
  • 19
    Nogueira March JL, Solsona E, Unda M et al. A multicenter and randomized prospective study comparing three intravesical therapies, two with bacillus Calmette-Guerin immunotherapy and one with Mitomycin C- chemotherapy in medium and low risk superficial bladder tumors. Eur Urol 2000; 37 (Suppl. 2): 112 (Abstract 447)
  • 20
    De Boer E, Kolk AH, Kuijper S, Kurth KH, Schamhart DH. On the number of bacillus Calmette-Guerin (BCG) bacteria, inducing an immune response in the Guinea pig. J Urol 1997; 157: 384 (Abstract 1503)
  • 21
    Bartlett GL, Zbar B, Rapp HJ. Suppression of murine tumor growth by immune reaction to the Bacillus Calmette-Guerin strain of Mycobacterium bovis. J Natl Cancer Inst 1972; 48: 2457
  • 22
    Böhle A, for the EBIN Group. BCG's mechanism of action – Increasing our understanding. Eur Urol 2000; 37 (Suppl. 1): 18
  • 23
    Smith JA, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder Cancer Clinical Guidelines Pannel Summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis). J Urol 1999; 162: 1697701
  • 24
    Resel Folkersma L, Belon JA, Isorna S, Carnicero Luna JA. Complicaciones del tratamiento endovesical con BCG en una serie de doscientos pacientes. Arch Esp Urol 1999; 52: 95765
  • 25
    Bassi P, Spinardi R, Carando R, Balta G, Pagano F. Modified Induction Course: a solution to side effects? Eur Urol 2000; 37: 312
  • 26
    Zlotta AR, Van Vooren JP, Huygen K et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000; 37: 4707
Abbreviations
CUETO

Club Urológico Espan˜ol de Tratamiento Oncológico

RD

reduced dose

HR

hazard ratio.